Your browser doesn't support javascript.
loading
Patient-Reported Survivorship Care Practices and Late Effects After Treatment of Hodgkin and Non-Hodgkin Lymphoma.
Frick, Melissa A; Vachani, Carolyn C; Hampshire, Margaret K; Bach, Christina; Arnold-Korzeniowski, Karen; Metz, James M; Hill-Kayser, Christine E.
Afiliação
  • Frick MA; All authors: University of Pennsylvania, Philadelphia, PA.
  • Vachani CC; All authors: University of Pennsylvania, Philadelphia, PA.
  • Hampshire MK; All authors: University of Pennsylvania, Philadelphia, PA.
  • Bach C; All authors: University of Pennsylvania, Philadelphia, PA.
  • Arnold-Korzeniowski K; All authors: University of Pennsylvania, Philadelphia, PA.
  • Metz JM; All authors: University of Pennsylvania, Philadelphia, PA.
  • Hill-Kayser CE; All authors: University of Pennsylvania, Philadelphia, PA.
JCO Clin Cancer Inform ; 2: 1-10, 2018 12.
Article em En | MEDLINE | ID: mdl-30652594
ABSTRACT

PURPOSE:

Multimodal treatment of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) yields excellent outcomes; however, survivors are at risk of developing myriad late and long-term effects.

METHODS:

From a convenience sample of 964 survivors of HL (37%) and NHL (63%) using a publicly available Internet-based survivorship care plan (SCP) tool between 2011 and 2016, we examined patient-reported cancer care, toxicities, and survivorship care data.

RESULTS:

Of all survivors, 67% were female and 84% were white and 88% were free of cancer. Median age of diagnosis was 28 years for survivors of HL and 49 years for NHL. Many survivors reported treatment with chemotherapy (92%), surgery (52%), and/or radiation (41%), with most radiation delivered to chest/mantle fields (81%). Survivors reported a diversity of radiation- and chemotherapy-related sequelae, including thyroid dysfunction, speaking and/or swallowing changes, pulmonary fibrosis/pneumonitis, heart disease, chronic fatigue, neurocognitive decline, neuropathy, sexual changes, and secondary breast cancers. Few reported receipt of previous survivorship information. Most reported management/comanagement by an oncology specialist after active treatment; however, a shift to management by primary care provider alone was observed as a trend over time in follow-up. Sixty-six percent of users who responded to a follow-up survey reported that they intend to share the SCP with their health care team.

CONCLUSION:

Survivors of lymphoma, many of whom are free of disease, report a substantial burden of late and long-term adverse effects, suboptimal delivery of survivorship information, and transitions of care in follow-up in which fragmented systems and/or poor communication may contribute to unmet survivor needs. Multiple opportunities thus exist for which SCPs may be used to improve awareness regarding survivorship and associated adverse effects in addition to communicating follow-up care plans between survivors and treatment teams.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma não Hodgkin / Doença de Hodgkin / Terapia Combinada / Medidas de Resultados Relatados pelo Paciente Tipo de estudo: Guideline Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma não Hodgkin / Doença de Hodgkin / Terapia Combinada / Medidas de Resultados Relatados pelo Paciente Tipo de estudo: Guideline Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article